Cochlear Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Cochlear de 12.2% y 8.4% por año respectivamente. Se prevé que el BPA crezca en un 12.2% al año. Se espera que la rentabilidad financiera sea de 24.5% en 3 años.

Información clave

12.2%

Tasa de crecimiento de los beneficios

12.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.7%
Tasa de crecimiento de los ingresos	8.4%
Rentabilidad financiera futura	24.5%
Cobertura de analistas	Good
Última actualización	10 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Cochlear Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 20

Recent updates

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 04

Cochlear (ASX:COH) Could Be Struggling To Allocate Capital

Sep 12

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Jun 05

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Apr 05

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Mar 04

Is Cochlear (ASX:COH) A Risky Investment?

Dec 19

Is Cochlear Limited (ASX:COH) Worth AU$205 Based On Its Intrinsic Value?

Nov 16

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Oct 25

Should Shareholders Reconsider Cochlear Limited's (ASX:COH) CEO Compensation Package?

Oct 11

Cochlear's (ASX:COH) Upcoming Dividend Will Be Larger Than Last Year's

Aug 28

Here's Why Cochlear (ASX:COH) Can Manage Its Debt Responsibly

Aug 23

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Jul 16

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

May 19

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Apr 09

Estimating The Intrinsic Value Of Cochlear Limited (ASX:COH)

Feb 04

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Dec 24

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Oct 30

This Is Why We Think Cochlear Limited's (ASX:COH) CEO Might Get A Pay Rise Approved By Shareholders

Oct 12

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Oct 06

Returns On Capital Signal Tricky Times Ahead For Cochlear (ASX:COH)

Aug 16

Cochlear (ASX:COH) Has A Pretty Healthy Balance Sheet

Jun 24

A Look At The Intrinsic Value Of Cochlear Limited (ASX:COH)

May 17

There Are Reasons To Feel Uneasy About Cochlear's (ASX:COH) Returns On Capital

Apr 29

These 4 Measures Indicate That Cochlear (ASX:COH) Is Using Debt Reasonably Well

Mar 20

Insider Buying: The Cochlear Limited (ASX:COH) Independent Non-Executive Director Just Bought 24% More Shares

Mar 02

Cochlear Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 20

Calculating The Intrinsic Value Of Cochlear Limited (ASX:COH)

Feb 11

Our Take On The Returns On Capital At Cochlear (ASX:COH)

Jan 25

Do Institutions Own Cochlear Limited (ASX:COH) Shares?

Jan 07

Introducing Cochlear (ASX:COH), The Stock That Zoomed 107% In The Last Five Years

Dec 21

How Much Is Cochlear Limited (ASX:COH) CEO Getting Paid?

Dec 06

Does Cochlear (ASX:COH) Have A Healthy Balance Sheet?

Nov 18

Previsiones de crecimiento de beneficios e ingresos

ASX:COH - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2026	2,700	503	486	590	15
6/30/2025	2,495	444	417	521	16
6/30/2024	2,276	392	354	449	16
12/31/2023	2,149	350	335	430	N/A
9/30/2023	2,043	326	301	396	N/A
6/30/2023	1,936	301	267	362	N/A
3/31/2023	1,824	281	263	352	N/A
12/31/2022	1,713	261	259	341	N/A
9/30/2022	1,681	275	279	359	N/A
6/30/2022	1,648	289	299	377	N/A
3/31/2022	1,612	273	266	340	N/A
12/31/2021	1,575	257	233	304	N/A
9/30/2021	1,536	291	216	285	N/A
6/30/2021	1,498	324	199	265	N/A
3/31/2021	1,403	82	-52	34	N/A
12/31/2020	1,308	-160	-302	-198	N/A
9/30/2020	1,314	-199	-295	-178	N/A
6/30/2020	1,321	-238	-288	-158	N/A
3/31/2020	1,400	34	-80	50	N/A
12/31/2019	1,479	306	128	259	N/A
9/30/2019	1,453	291	155	277	N/A
6/30/2019	1,427	277	181	296	N/A
3/31/2019	1,422	270	217	313	N/A
12/31/2018	1,418	264	252	330	N/A
9/30/2018	1,391	255	230	294	N/A
6/30/2018	1,364	246	208	258	N/A
3/31/2018	1,329	234	194	254	N/A
12/31/2017	1,294	223	180	250	N/A
9/30/2017	1,274	223	N/A	255	N/A
6/30/2017	1,254	224	N/A	260	N/A
3/31/2017	1,218	215	N/A	237	N/A
12/31/2016	1,182	206	N/A	214	N/A
9/30/2016	1,156	198	N/A	199	N/A
6/30/2016	1,131	189	N/A	185	N/A
3/31/2016	1,088	179	N/A	179	N/A
12/31/2015	1,045	168	N/A	172	N/A
9/30/2015	986	157	N/A	181	N/A
6/30/2015	926	146	N/A	189	N/A
3/31/2015	899	145	N/A	178	N/A
12/31/2014	872	144	N/A	168	N/A
9/30/2014	839	119	N/A	140	N/A
6/30/2014	805	94	N/A	111	N/A
3/31/2014	769	85	N/A	93	N/A
12/31/2013	732	76	N/A	75	N/A
9/30/2013	742	104	N/A	72	N/A
6/30/2013	753	133	N/A	70	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (12.2% al año) de COH es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: Se prevé que los beneficios (12.2% al año) de COH crezcan menos que el mercado Australian (13.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de COH crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (8.4% al año) de COH crezcan más rápidamente que los del mercado Australian (4.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 8.4% al año) de COH crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de COH sea alta dentro de 3 años (24.5%)

Cochlear Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.0% to AU$272

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited Provides Earnings Guidance for the Fiscal Year 2022

Cochlear Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Cochlear Limited Announces Company Secretary Changes

Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Upcoming dividend of AU$2.00 per share

First half dividend increased to AU$2.00

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

First half 2024 earnings: EPS in line with expectations, revenues disappoint

Price target increased by 7.0% to AU$272

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Cochlear (ASX:COH) Could Be Struggling To Allocate Capital

Upcoming dividend of AU$1.75 per share at 1.2% yield

Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 T

Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Upcoming dividend of AU$1.55 per share at 1.3% yield

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Is Cochlear (ASX:COH) A Risky Investment?

Cochlear Limited, Annual General Meeting, Oct 17, 2023

Is Cochlear Limited (ASX:COH) Worth AU$205 Based On Its Intrinsic Value?

FDA Approves Cochlear Limited's Nucleus 8 Sound Processor, Smaller, Smarter, Better Connected Cochlear Implant Technology

Key Executive recently bought AU$97k worth of stock

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Should Shareholders Reconsider Cochlear Limited's (ASX:COH) CEO Compensation Package?

Upcoming dividend of AU$1.45 per share

Cochlear's (ASX:COH) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why Cochlear (ASX:COH) Can Manage Its Debt Responsibly

Full year 2022 earnings: EPS misses analyst expectations

Cochlear Announces Final Dividend Payable on 17 October 2022

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Cochlear Limited Appoints Karen Penrose to Board, Effective on 1 July 2022

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Cochlear Limited, Annual General Meeting, Oct 18, 2022

Cochlear Limited to Report First Half, 2023 Results on Feb 15, 2023

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Upcoming dividend of AU$1.55 per share

Investor sentiment improved over the past week

First half 2022 earnings: EPS and revenues exceed analyst expectations

Cochlear Limited Announces Interim Dividend Expected to Be Payable on 21 April 2022

Estimating The Intrinsic Value Of Cochlear Limited (ASX:COH)

FDA Approves Cochlear Nucleus Implants for Unilateral Hearing Loss/Single-Sided Deafness

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Independent Non-Executive Director recently bought AU$56k worth of stock

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

This Is Why We Think Cochlear Limited's (ASX:COH) CEO Might Get A Pay Rise Approved By Shareholders

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Cochlear Limited Advises of US Patent Infringement Complaint

Upcoming dividend of AU$1.40 per share

CEO, MD exercised options and sold AU$295k worth of stock

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Independent Non-Executive Director recently bought AU$94k worth of stock

Independent Chairman Roderic Holliday-Smith has left the company

Independent Chairman Roderic Holliday-Smith has left the company

Full year 2021 earnings released: EPS AU$4.97 (vs AU$4.00 loss in FY 2020)

Cochlear Limited Provides Earnings Guidance for the Fiscal Year 2022

Returns On Capital Signal Tricky Times Ahead For Cochlear (ASX:COH)

Non-Executive Independent Director Abbas Hussain has left the company

Cochlear (ASX:COH) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of Cochlear Limited (ASX:COH)

New Cochlear CoPilot app to help adults improve hearing outcomes through skills training

There Are Reasons To Feel Uneasy About Cochlear's (ASX:COH) Returns On Capital

These 4 Measures Indicate That Cochlear (ASX:COH) Is Using Debt Reasonably Well

Upcoming Dividend of AU$1.15 Per Share

Cochlear Receives FDA Clearance of Baha 6 Max, Industry's Smallest 55 dB Sound Processor Now with Direct Android Streaming

Insider Buying: The Cochlear Limited (ASX:COH) Independent Non-Executive Director Just Bought 24% More Shares

Independent Non-Executive Director recently bought AU$164k worth of stock